A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.

Autor: Chan A; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Republic of Singapore., Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2015 Aug; Vol. 23 (8), pp. 2231-44. Date of Electronic Publication: 2015 Jan 07.
DOI: 10.1007/s00520-014-2564-x
Abstrakt: Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL.
Methods: A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments.
Results: Thirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16©, Skindex-29©, Dermatology Life Quality Index (DLQI), and DIELH-24) and two were symptom-specific (functional assessment of cancer therapy-epidermal growth factor receptor inhibitor-18 (FACT-EGFRI-18) and hand-foot syndrome 14 (HFS-14)).
Conclusions: While there are several PRO instruments that have been tested in the context of targeted cancer therapy, additional work is needed to develop new instruments and to further validate the instruments identified in this study in patients receiving targeted therapies.
Competing Interests: AND SOURCES OF FUNDING There were no sources of funding used in this study. The authors have full control of the primary data, which is available to the journal at their request for review. Dr. Roeland has a consultant role with Cellulitix. Dr. Choi has received remuneration from Onyx Pharmaceuticals and has a consultant role with Biotest AG. Dr. Bryce has a consultant role with AstraZeneca and Roche. Dr. Gerber has a consultant role with Galderma International. He is also receiving research funding from Hoffman La Roche. Dr. Lacouture has a consultant role with AstraZeneca, Roche, Bayer, Janssen, Exelixis, Advancell, BMS, Amgen, and Genentech. He is also receiving research funding from Berg, Roche and BMS.
Databáze: MEDLINE
Externí odkaz: